Recommended Starting Dilutions:
For WB: Use at a dilution of 1:100-1:3000. Recognizes a band at 118kDa.
For IHC: Use at a dilution of 1:100.
For ICC/IF: Use at a dilution of 1:100-1:1000.
Optimal dilutions/concentrations should be determined by the researcher.
Hypoxic lysates , HepG2 (1% O2 treatment for 24hr and using Urea buffer) , Myc-DDK human HIF2A-transfected 293T
Specific for HIF-2 alpha/EPAS. Does not cross react with HIF-1 alpha.
1XPBS, 20% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
A peptide derived from the mouse/human HIF-2 alpha.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
endothelial PAS domain protein 1 , HIF-2alpha , HIF2A , HLF , HRF , MOP2 , bHLHe73
Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. HIF-2 alpha is predominantly expressed in highly vascularized tissues of adult humans and endothelial cells of the embryonic and adult mouse, whereas HIF-1alpha functions primarily in extravascular tissues. HIF-2 alpha is also a potent activator of the tie-2 gene, which is known to be selectively expressed in endothelial cells. (1)